Physician profile
Mark Sheynshteyn
NPI 1447517883
$16,703.72
in general payments reported to CMS, 2019-2025
52 companies · $3,682 in 2025
The $3,682 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $1,868 · 2021: $1,858 · 2022: $2,913 · 2023: $3,300 · 2024: $2,616 · 2025: $3,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,141 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,435 · Education: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,140.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,435.00 |
| Education | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,076.98 | 2020-2025 | Korlym |
| Novo Nordisk INC | $1,994.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,176.55 | 2019-2024 | Farxiga, Lokelma |
| Medtronic, INC. | $1,052.87 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $991.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $951.15 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $852.27 | 2020-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $796.45 | 2019-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $703.60 | 2020-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $680.95 | 2019-2025 | |
| Abbvie INC. | $668.07 | 2020-2025 | Synthroid |
| Insulet Corporation | $552.70 | 2020-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $532.36 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.73 | 2021-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $362.16 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sheynshteyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.